2. Accepting Lepidico Shareholders won’t risk dilution in Lepidico
Lepidico Shareholders who accept the Offers will not have to face the choice of:
o investing more money in Lepidico under the Lepidico Entitlement Offer, or
o have your holding diluted as a consequence of the Lepidico Entitlement Offer.
Lepidico Shareholders can avoid this choice by swapping their LPD Shares for LIT Shares and still retain exposure to Lepidico’s assets through Lithium Australia’s holding in Lepidico.
5. Avoid exposure to Lepidico’s long term funding risk
In the Lepidico Target Statement, Lepidico’s Independent Expert states that:
“To raise an equivalent US million required to fund the development of the [Lepidico] Project, approximately 5,944,444,444 new Lepidico shares will need to be issued resulting in a total of 7,694,982,035 Lepidico shares on issue”
Hmmm.... so we retain exposure while also avoiding it. ???
They spend a fair bit of time talking down Lepedico's planning for a company that is about to acquire a lot of their shares!
- Forums
- ASX - By Stock
- Ann: LIT: First Supplementary Bidder's Statement
2. Accepting Lepidico Shareholders won’t risk dilution in...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LPD (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.17M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.2¢ | $2.976K | 1.192M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
81 | 101053096 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 85503236 | 56 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
68 | 93807513 | 0.002 |
77 | 175080865 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 65393118 | 53 |
0.004 | 25028176 | 32 |
0.005 | 12046941 | 12 |
0.006 | 2391995 | 7 |
0.007 | 1047189 | 5 |
Last trade - 15.48pm 08/11/2024 (20 minute delay) ? |
Featured News
LPD (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online